ライフサイエンスコーパス: chemotherapy regimen

1 ists have control (eg, surgical technique or chemotherapy regimen).

2 a lower intensity version of the first-line chemotherapy regimen).

3 he control group; 14 matched by both age and chemotherapy regimen).

4 d failed one previous doxorubicin-containing chemotherapy regimen.

5 ysis to identify the most effective adjuvant chemotherapy regimen.

6 se characteristics, and myelotoxicity of the chemotherapy regimen.

7 0 had received at least one prior metastatic chemotherapy regimen.

8 he stratification factors of age and planned chemotherapy regimen.

9 umour size, clinical stage, and prespecified chemotherapy regimen.

10 plus docetaxel is an appropriate first-line chemotherapy regimen.

11 nostic procedures and 37% involved choice of chemotherapy regimen.

12 0; n = 54) as part of an otherwise identical chemotherapy regimen.

13 during or after a first-line platinum-based chemotherapy regimen.

14 ail reminders timed to the start of each new chemotherapy regimen.

15 efinitive treatment, with no known effective chemotherapy regimen.

16 omparable with Headstart, a standard-of-care chemotherapy regimen.

17 hormone receptor status, clinical stage, and chemotherapy regimen.

18 fully treated with a mildly myelosuppressive chemotherapy regimen.

19 aily, or placebo until there was a change of chemotherapy regimen.

20 irectly observe the efficacy of a particular chemotherapy regimen.

21 eeks or 10 mg/kg every 2 weeks, depending on chemotherapy regimen.

22 (NSCLC) includes the use of a platinum-based chemotherapy regimen.

23 se characteristics, and myelotoxicity of the chemotherapy regimen.

24 MS and lymphoma patients receiving the same chemotherapy regimen.

25 rded with frequently reported events for the chemotherapy regimen.

26 tive trials are needed to define the optimal chemotherapy regimen.

27 s treatment with at least one platinum-based chemotherapy regimen.

28 , number of metastatic sites, and first-line chemotherapy regimen.

29 nd received at least one previous multiagent chemotherapy regimen.

30 ymphoma who previously received at least one chemotherapy regimen.

31 alignancies with this doxorubicin-containing chemotherapy regimen.

32 nse and EFS in TNBC patients under different chemotherapy regimens.

33 egarding the use of ATR inhibitors in cancer chemotherapy regimens.

34 ted to improve responses to standard-of-care chemotherapy regimens.

35 LMO2-driven leukemias resistant to existing chemotherapy regimens.

36 (HL) tend to be poor following conventional chemotherapy regimens.

37 C biology and in identifying best-performing chemotherapy regimens.

38 to 65% to 70% after the advent of multiagent chemotherapy regimens.

39 me due to its refractoriness to conventional chemotherapy regimens.

40 and liver during treatment with 2 different chemotherapy regimens.

41 ved fluorouracil- and oxaliplatin-containing chemotherapy regimens.

42 ting the cancer plasma cell population using chemotherapy regimens.

43 ser therapy to treat OM induced by different chemotherapy regimens.

44 s a curable disease with currently available chemotherapy regimens.

45 of conventional all-trans retinoic acid plus chemotherapy regimens.

46 ies and showed no difference between the two chemotherapy regimens.

47 s failed to respond to at least two previous chemotherapy regimens.

48 y and, thus, improved efficacy over standard chemotherapy regimens.

49 ment failure with one to two prior cytotoxic chemotherapy regimens.

50 n tube carcinoma with a maximum of two prior chemotherapy regimens.

51 mab or among patients treated with different chemotherapy regimens.

52 ve studies suggest a benefit for combination chemotherapy regimens.

53 iven a median of three (range 1-16) previous chemotherapy regimens.

54 had been treated with three or more previous chemotherapy regimens.

55 agulation therapy, and safety with differing chemotherapy regimens.

56 uses of drugs and biologicals in anticancer chemotherapy regimens.

57 BL may be used to design "immunostimulatory" chemotherapy regimens.

58 taxane is the sequence used in most adjuvant chemotherapy regimens.

59 ated with standard or only slightly modified chemotherapy regimens.

60 lement of supportive care for many high-dose chemotherapy regimens.

61 ences in selection of breast cancer adjuvant chemotherapy regimens.

62 hout adjuvant chemotherapy, and by differing chemotherapy regimens.

63 h agents, and 47.7% had received three prior chemotherapy regimens.

64 hemotherapy, and 18 (9%) required additional chemotherapy regimens.

65 ing drug resistance and for tailoring cancer chemotherapy regimens.

66 who will receive one of the widely-accepted chemotherapy regimens.

67 be effective in cells resistant to existing chemotherapy regimens.

68 eloping new anticancer drugs and combination chemotherapy regimens.

69 despite the use of multi-agent conventional chemotherapy regimens.

70 the toxicity and deliverability of standard chemotherapy regimens.

71 successfully treated with a cisplatin-based chemotherapy regimen adequate for stage.

72 The optimal chemotherapy regimen administered concurrently with preo

73 t and Bowel Project trial R-04 compared four chemotherapy regimens administered concomitantly with RT

74 ation (chemotherapy first [CT1]) or the same chemotherapy regimen after radiation (radiation therapy

75 -stage regression trial with three different chemotherapy regimens, alone or in combination with the

76 with GCT who received a cisplatin-containing chemotherapy regimen and had available tumor tissue were

77 effects were related to the lymphodepleting chemotherapy regimen and included lymphopenia, neutropen

78 Treatment, defined as specific chemotherapy regimen and number of cycles, was allocated

79 questions remain about the ideal concurrent chemotherapy regimen and optimal management of patients

80 arcinoma [mUC]) who progressed on >= 1 prior chemotherapy regimen and/or programmed death-1 receptor/

81 mly assigned 1:1 to two different dose-dense chemotherapy regimens and 2:1 to ibandronate 50 mg per d

82 ave continued to remain reliant on cytotoxic chemotherapy regimens and allogeneic hematopoietic cell

83 nase inhibitor, despite the use of high-risk chemotherapy regimens and frequent HSCT upon first remis

84 of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after

85 Both standard chemotherapy regimens and mAbs directed against ATLL tum

86 ment and recovery of bone marrow by specific chemotherapy regimens and may also enable imaging of org

87 Alternative chemotherapy regimens and neoadjuvant chemoradiation are

88 patients receiving adjuvant docetaxel-based chemotherapy regimens and occurred similarly in patients

89 eceived at least two previous platinum-based chemotherapy regimens and responded to their last platin

90 er previously treated with one or two taxane chemotherapy regimens and with an Eastern Cooperative On

91 Subset analyses evaluating histology, chemotherapy regimen, and incremental COX-2 expression d

92 All patients had received at least two prior chemotherapy regimens, and 17 patients had undergone pri

93 m cell transplant or two previous multiagent chemotherapy regimens, and for patients with relapsed or

94 exposure to radiation therapy, four or more chemotherapy regimens, and more than 5 days of apheresis

95 the evolution of gliomas during conventional chemotherapy regimens, and open new avenues for the sear

96 easures included: first, number and types of chemotherapy regimens, and second, frequency and timing

97 he community received less-toxic and shorter chemotherapy regimens, and those treated had fewer adver

98 ial design to define whether six cycles of a chemotherapy regimen are superior to four cycles.

99 Different adjuvant chemotherapy regimens are available for early-stage brea

100 Because anthracycline-based chemotherapy regimens are standard treatment for TNBC, w

101 (EGFR) -targeted therapies and conventional chemotherapy regimens are warranted in clinical practice

102 ressive HIV-non-Hodgkin lymphoma, infusional chemotherapy regimens are well tolerated and lead to com

103 chemoradiotherapy to 64.3 Gy, with the same chemotherapy regimen as in the induction phase.

104 e, and paclitaxel plus gemcitabine (the same chemotherapy regimen as the other group, with the additi

105 regimens derive the same benefits from newer chemotherapy regimens as younger patients but should be

106 Modifications in the chemotherapy regimens, as well as in perioperative care

107 ease, with methotrexate-vinblastine the only chemotherapy regimen assessed in a clinical trial settin

108 This study confirms that all chemotherapy regimens assessed have very modest efficacy

109 ed one of the two protocol-approved standard chemotherapy regimens before randomisation.

110 nclude surgery in combination with cytotoxic chemotherapy regimens, biologics, and/or radiotherapy.

111 AAML03P1 and AAML0531 arm B, with identical chemotherapy regimens but with different toxicity report

112 Current standard care uses various cytotoxic chemotherapy regimens, but responses are seldom durable.

113 are important components of prostate cancer chemotherapy regimens, but their oral administration is

114 and cisplatin remain the most commonly used chemotherapy regimens, but work is ongoing to develop ne

115 re have been attempts to optimise multi-drug chemotherapy regimens by focusing on improving survival

116 min use will facilitate greater adherence to chemotherapy regimens by reducing mucositis.

117 as cytogenetic high risk, receive intensive chemotherapy (regimen C), and will only be recommended f

118 nto a 3-month adriamycin/cytoxan neoadjuvant chemotherapy regimen can predict final, postsurgical pat

119 These systemic chemotherapy regimens can also be applied both preoperat

120 Neoadjuvant radio/chemotherapy regimens can markedly improve cervical canc

121 Chart review examined chemotherapy regimens, cardiac risk factors, imaging res

122 m that the addition of rituximab to standard chemotherapy regimens (chemoimmunotherapy) improves both

123 mab combined with either mFOLFOX6 or FOLFIRI chemotherapy regimen chosen by the treating physician an

124 With the data for the two chemotherapy regimens combined, the addition of bevacizu

125 d in 23.8% of patients receiving three prior chemotherapy regimens, compared with 0% of patients rece

126 ted radiotherapy (STRT) followed by a common chemotherapy regimen consisting of eight cycles of cispl

127 y assigned 302 patients to receive induction chemotherapy regimens consisting of cytosine arabinoside

128 ession who exhibit reduced responsiveness to chemotherapy regimens containing doxorubicin.

129 dy irradiation, radiation to the gonads, and chemotherapy regimens containing high-dose alkylators ca

130 The preferred chemotherapy regimen contains a platinum agent and etopo

131 re randomly assigned to one of the following chemotherapy regimens: continuous intravenous infusional

132 rituximab (1400 mg), stratified by induction chemotherapy regimen (cyclophosphamide, doxorubicin, vin

133 Elderly patients treated with newer adjuvant chemotherapy regimens derive the same benefits from newe

134 The overall number of chemotherapy regimens did not differ significantly by st

135 ion renders cells more sensitive to standard chemotherapy regimen due to a DNA repair defect.

136 o interaction between treatment duration and chemotherapy regimen, ER/PgR, or HER2 status on RFS or O

137 Risk was raised after each common chemotherapy regimen except, based on limited numbers an

138 ast cancer receiving adjuvant or neoadjuvant chemotherapy regimens excluding sequential or combinatio

139 ular lymphoma by administering a preparative chemotherapy regimen followed by autologous T cells gene

140 eatment with an anthracycline-based adjuvant chemotherapy regimen followed by high-dose chemotherapy

141 d-line therapy typically includes multiagent chemotherapy regimens followed by autologous stem cell t

142 il (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesoph

143 arm) alone in patients receiving their first chemotherapy regimen for CLL.

144 The chemotherapy regimen for each patient was selected befor

145 ) is an established and effective first-line chemotherapy regimen for metastatic colorectal cancer.

146 n and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary

147 There is currently no standard chemotherapy regimen for patients with lymphoid malignan

148 m selection of a bladder-sparing trimodality chemotherapy regimen for patients with muscle invasive b

149 rial was designed to select a cetuximab plus chemotherapy regimen for phase III evaluation.

150 There is no standard chemotherapy regimen for relapsed disease, although a fe

151 is study started, the standard postoperative chemotherapy regimen for stage II-III Wilms' tumour pret

152 rting the need for a more intensive adjuvant chemotherapy regimen for this subgroup.

153 ged adults who receive a pediatric-intensive chemotherapy regimen for treatment of Philadelphia chrom

154 n essential component of primary and salvage chemotherapy regimens for acute myeloid leukemia (AML).

155 ideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuva

156 ideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer including

157 of hair loss among women receiving specific chemotherapy regimens for early-stage breast cancer and

158 The purpose of this study was to compare two chemotherapy regimens for LGGs in children younger than

159 from N9741, a randomized phase III trial of chemotherapy regimens for metastatic colorectal cancer,

160 prior platinum; breast cancer with >/= three chemotherapy regimens for metastatic disease; pancreatic

161 C who had received no more than two previous chemotherapy regimens for mTNBC were randomly allocated

162 oxic effects than with alternative available chemotherapy regimens for patients with advanced melanom

163 Doxorubicin forms the basis of chemotherapy regimens for several malignancies, includin

164 tern Europe vs or other), number of previous chemotherapy regimens for unresectable, locally advanced

165 -risk metastatic disease receive combination chemotherapy regimens from the start.

166 administration of a component of the initial chemotherapy regimen, generally the nonplatinum cytotoxi

167 urther therapies should take into account of chemotherapy regimen, genotypes of metabolizing enzymes

168 eceived at least two previous platinum-based chemotherapy regimens, had achieved complete or partial

169 , risk-based Lymphome Malin de Burkitt (LMB) chemotherapy regimen has improved survival rates for chi

170 requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified.

171 Current research suggests that standard chemotherapy regimens have been optimized to maximal eff

172 Platinum-doublet chemotherapy regimens have been shown to extend survival

173 Some chemotherapy regimens have been well established as firs

174 ositive patients treated with newer adjuvant chemotherapy regimens have improvements in relapse-free

175 Intensive chemotherapy regimens have led to a substantial improvem

176 Anthracycline- and taxane-based three-drug chemotherapy regimens have proven benefit as adjuvant th

177 ho had received rituximab in addition to the chemotherapy regimen (hazard ratio, 3.3; 95% CI, 1.0-14.

178 rospectively reviewed clinical presentation, chemotherapy regimens, hematologic response, and renal a

179 tion procedure was used, taking into account chemotherapy regimen, histology, addition or not of beva

180 se observation if scans are clear to various chemotherapy regimens, hormonal treatment, and surgery.

181 ly through the application of platinum-based chemotherapy regimens; however, clinical challenges in G

182 dy therapy with rituximab into the intensive chemotherapy regimen hyper-CVAD (fractionated cyclophosp

183 ic cell transplantation or two or more prior chemotherapy regimens if ineligible for autologous hemat

184 afety of adding nelarabine to a BFM 86-based chemotherapy regimen in children with newly diagnosed T-

185 n added to a standard carboplatin/paclitaxel chemotherapy regimen in patients with newly diagnosed ad

186 ion (TBI) to the preparative lymphodepleting chemotherapy regimen in sequential trials improved objec

187 sion on or after one previous platinum-based chemotherapy regimen in the metastatic setting.

188 The use of pediatric intensive combination chemotherapy regimens in adolescents and young adults ha

189 here is little information on using standard chemotherapy regimens in AML xenografts.

190 critical importance of an adherence to oral chemotherapy regimens in attaining cure for children wit

191 ent use of non-guideline-concordant adjuvant chemotherapy regimens in black women and women with lowe

192 ized phase II trial to investigate two novel chemotherapy regimens in combination with concurrent tho

193 of novel hormonal agents and life-prolonging chemotherapy regimens in combination with standard andro

194 chieving an objective response compared with chemotherapy regimens in ipilimumab-refractory patients

195 II/III trial comparing two carboplatin-based chemotherapy regimens in patients with urothelial cancer

196 coids are critical components of combination chemotherapy regimens in pediatric acute lymphoblastic l

197 AD/CVAD) or intensive (hyper-CVAD) frontline chemotherapy regimens in the pre-rituximab era.

198 metastatic NSCLC received similar numbers of chemotherapy regimens in the sample, early palliative ca

199 Most chemotherapy regimens included anthracyclines, taxanes,

200 Chemotherapy regimens included doublet therapy, single-a

201 Adjuvant chemotherapy regimens included in any of several publish

202 essed as a predictive marker in a variety of chemotherapy regimens including anthracyclines.

203 All patients who receive highly emetogenic chemotherapy regimens (including anthracycline plus cycl

204 Patients previously treated with one to two chemotherapy regimens (including one platinum-based regi

205 Combination chemotherapy regimen incorporating CD20 antibodies are c

206 erior among those who had received intensive chemotherapy regimens instead of lower-dose regimens.

207 The extension of 'pediatric-inspired' chemotherapy regimens into young and middle-age adults h

208 Choosing the optimal chemotherapy regimen is still an unmet medical need for

209 l dose administered as a low-dose metronomic chemotherapy regimen largely prevented therapy-induced s

210 ship has improved with current radiation and chemotherapy regimens, long-term effects have been ident

211 ory disease, or progression on more than two chemotherapy regimens (metastatic setting) was not allow

212 mia burden prior to transplantation, salvage chemotherapy regimens need to be employed.

213 All patients received the same chemotherapy regimen of bortezomib and dexamethasone.

214 Patients received a conditioning chemotherapy regimen of cyclophosphamide and fludarabine

215 h cHL between 1989 and 2012 treated with the chemotherapy regimen of doxorubicin, bleomycin, vinblast

216 ts, such as the recent promising combination chemotherapy regimen of folinic acid (leucovorin), fluor

217 e nodes, we found no evidence that extending chemotherapy regimens of AC or single-agent T from four

218 opathological response to fluorouracil-based chemotherapy regimens, of which the FAD binding protein

219 e necessary to determine the impact of newer chemotherapy regimens on survival.

220 s had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combin

221 Independent of preoperative chemotherapy regimen, optimal morphologic response is su

222 T) and recurrence after at least one salvage chemotherapy regimen or with anaplastic histology Wilms'

223 Furthermore, combining TMP195 with chemotherapy regimens or T-cell checkpoint blockade in t

224 ittle is known regarding the use of specific chemotherapy regimens or treatment duration.

225 These patients may benefit from intensified chemotherapy regimens or, ideally, should enroll in clin

226 t to receive chemotherapy, 12 (2%) chose one chemotherapy regimen over another, six (1%) considered n

227 ared with 0% of patients receiving two prior chemotherapy regimens (P < .01).

228 ce status, histology, and number of previous chemotherapy regimens, patients were randomly assigned (

229 platin [area under the curve 5]) or the same chemotherapy regimen plus bevacizumab (15 mg/kg of bodyw

230 75 mg/m(2) of body surface area) or the same chemotherapy regimen plus bevacizumab 7.5 mg per kg body

231 expansion in the use of improved combination chemotherapy regimens plus or minus biologics, to render

232 Solid tumor chemotherapy regimens pose a risk for hepatitis B virus

233 rubicin, bleomycin, vinblastine, dacarbazine chemotherapy regimen, prescribed for nearly all patients

234 375 mg/m(2) on days -19 and -12 and the same chemotherapy regimen (R-BEAM).

235 in a 3:2:2:2 ratio, stratified by centre and chemotherapy regimen: radical radiotherapy alone (n=233)

236 ts had been given a median of three previous chemotherapy regimens (range 1-5 in cohort 1, and 2-4 in

237 ents had received a median of three previous chemotherapy regimens (range, one to seven), and 73% had

238 y injury and who received a bortezomib-based chemotherapy regimen relative to those receiving HF-HD.

239 Intensive chemotherapy regimens result in cure rates >85% in child

240 The chemotherapy regimens resulted in similar EFS and overal

241 The addition of cetuximab to these chemotherapy regimens results in an overall survival adv

242 Comparison of the three chemotherapy regimens revealed 84% of patients treated w

243 plus rituximab (BR) vs a standard rituximab-chemotherapy regimen (rituximab plus cyclophosphamide, d

244 nhibitor guadecitabine or a standard-of-care chemotherapy regimen selected by the treating physician.

245 ognostic factors-age, trial, number of prior chemotherapy regimens, sex, and race/ethnicity-were eval

246 In patients with hepatic CRM, the chemotherapy regimen should be carefully considered beca

247 Decisions regarding adjuvant chemotherapy regimens should take into account baseline

248 desmoid tumors remains a challenge, but new chemotherapy regimens show some promise in treating this

249 Both chemotherapy regimens significantly improved LFS compare

250 to select low-risk patients for abbreviated chemotherapy regimens similar to those used in our study

251 diagnosis and after a median of 2 different chemotherapy regimens, somatic mosaic PPM1D mutations in

252 sing permuted blocks sizes and stratified by chemotherapy regimen, stage of disease, histology, and s

253 ) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, le

254 iologic downstaging, vascular resection, and chemotherapy regimen/switch were not associated with sur

255 Chemotherapy regimens that combine anthracyclines and ta

256 n of SMPD1 was associated with resistance to chemotherapy regimens that include 5-FU.

257 One possibility is that standard chemotherapy regimens that include CYP3A substrates may

258 it to behave as an antagonist in combination chemotherapy regimens that include hPXR activators.

259 We compared two chemotherapy regimens that included methotrexate (MTX),

260 nephropathy treated with a bortezomib-based chemotherapy regimen, the use of high-cutoff hemodialysi

261 s an adverse risk factor for historical ATRA/chemotherapy regimens, the molecular bases for this effe

262 The optimal chemotherapy regimen to use with radiotherapy in stage I

263 nts were treated with intensive conditioning chemotherapy regimens to destroy the autoreactive immune

264 s had received between two and five previous chemotherapy regimens (two or more for advanced disease)

265 that trial has been difficult because of the chemotherapy regimen used (methotrexate with/without ifo

266 The 2 most common chemotherapy regimens used concurrently with thoracic ra

267 The intensive chemotherapy regimens used to treat acute myeloid leukae

268 Like classical chemotherapy regimens used to treat cancer, targeted the

269 Cooperative group studies have led to chemotherapy regimens using the same drugs (vincristine,

270 dition to their planned cisplatin-containing chemotherapy regimen, using permuted blocks of four.

271 safety of bevacizumab combined with standard chemotherapy regimens versus chemotherapy alone as secon

272 mab (BV) when combined with several standard chemotherapy regimens versus those regimens alone for fi

273 ibodies directed against CD20 into frontline chemotherapy regimens warrants investigation.

274 A busulfan-based chemotherapy regimen was used for bone marrow transplant

275 Addition of nelarabine to a BFM 86-based chemotherapy regimen was well tolerated and produced enc

276 patients treated, the median number of prior chemotherapy regimens was four (range, one to 11 regimen

277 king radiopharmaceutical into a contemporary chemotherapy regimen, we conducted a phase I study of do

278 ment who have difficulty tolerating existing chemotherapy regimens, we introduce small-molecule kinet

279 static cancer (N = 312) following at least 1 chemotherapy regimen were followed prospectively until d

280 s who had received no more than one previous chemotherapy regimen were randomly assigned on a 2:1 sch

281 ish, and who were scheduled to receive a new chemotherapy regimen were recruited from eight instituti

282 nsive first-line therapy and "lymphoid-type" chemotherapy regimens were associated with better outcom

283 open-label randomised arm in which high-dose chemotherapy regimens were compared.

284 ntolerance to at least two previous systemic chemotherapy regimens were enrolled.

285 who had relapsed after two or more previous chemotherapy regimens were randomly assigned (1:1) by an

286 All four cisplatin-based chemotherapy regimens were used: 377 (25%) patients rece

287 ent neuroblastoma (only one prior aggressive chemotherapy regimen) were randomly assigned to daily 5-

288 es for oxaliplatin-based or irinotecan-based chemotherapy regimens, were randomly assigned in a 1:1 r

289 ingle-agent chemotherapy receive alternative chemotherapy regimens, which, although effective, cause

290 e induction or fewer or received an adjuvant chemotherapy regimen, who had adequate organ function, a

291 serous ovarian cancer, treated with multiple chemotherapy regimens, who exhibited regression of some

292 ed afatinib with gemcitabine and cisplatin-a chemotherapy regimen widely used in Asia-for first-line

293 erlotinib to bevacizumab after a first-line chemotherapy regimen with bevacizumab for advanced non-s

294 Moreover, no chemotherapy regimen with or without targeted therapy is

295 latin, and should aid in designing cisplatin chemotherapy regimens with improved therapeutic indexes.

296 in patients with breast cancer who received chemotherapy regimens with low-to-intermediate risk of i

297 ned (1:1:1:1) to receive either of these two chemotherapy regimens with or without prior secondary cy

298 ive to historical controls who received this chemotherapy regimen without bevacizumab.

299 ant plus adjuvant bevacizumab to neoadjuvant chemotherapy regimens would also improve outcomes.

300 ncer and whether adding bevacizumab to these chemotherapy regimens would increase the rates of pathol